Analyst firms · Morgan Stanley · AKRO
Morgan Stanley AKRO price target and rating history
Akero Therapeutics Inc. (AKRO) · Health Care
Morgan Stanley rates Akero Therapeutics Inc. (AKRO) Overweight with a $65 price target, as of its latest action on Jan 27, 2023. It has published 3 rating actions on AKRO since October 2021, including 1 upgrade and 1 downgrade.
- Current rating
- Overweight
- Price target
- $65
- Median target, all firms
- Too few
- Actions on AKRO
- 3
Morgan Stanley price target on AKRO
Every Morgan Stanley rating on AKRO
- Jan 27, 2023
- Nov 15, 2021
- Oct 19, 2021
Questions about Morgan Stanley and AKRO
- What is Morgan Stanley's price target for AKRO?
- Morgan Stanley's latest stated price target for Akero Therapeutics Inc. (AKRO) is $65, from its action on Jan 27, 2023.
- What is Morgan Stanley's rating on AKRO?
- Morgan Stanley rates AKRO Overweight, a bullish rating, as of Jan 27, 2023.
- When did Morgan Stanley last change its view on AKRO?
- On Jan 27, 2023, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $40 to $65.
More AKRO rating histories
All Morgan Stanley ratingsAKRO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.